Extremely lately, preliminary benefits from a 3rd trial evaluating ibrutinib compared to observation ended up offered.one hundred and five Clients getting ibrutinib had an extended event-free of charge survival, but no Total survival edge, Even though the final results were even now immature. Moreover, Whilst significant adverse events prices had b